Hims & Hers Health Surges to 16th Most Actively Traded Stock with 45.78 Billion Shares Exchanged

Generated by AI AgentAinvest Volume Radar
Wednesday, Jul 23, 2025 7:37 pm ET1min read
Aime RobotAime Summary

- Hims & Hers Health surged to 16th most actively traded stock on July 23, 2025, with 45.78B shares traded (287.41% daily increase).

- Call option volumes spiked to 169,708 by 12:25 ET, exceeding 20-day average by 53.7% and historically correlating with price rallies.

- 36% short interest as of June 30 suggests potential upward pressure if forced short-covering occurs during ongoing rally.

- Upcoming August 4 earnings report will focus on weight-loss business performance amid Novo Nordisk controversies.

On July 23, 2025,

(HIMS) saw a significant surge in trading volume, with a total of 45.78 billion shares traded, marking a 287.41% increase from the previous day. This surge placed among the top 16 most actively traded stocks for the day. The company's stock price rose by 16.02%, marking the second consecutive day of gains and a total increase of 21.89% over the past two days.

Hims & Hers Health experienced a notable increase in call option volumes, with 169,708 call options traded by 12:25 p.m. ET. This volume exceeded the 20-day average of 110,459, indicating a significant spike in bullish options activity. Historically, Hims' largest rallies have coincided with similar spikes in call volumes, suggesting that options trading may be driving the recent price movement.

The company's short interest as a percentage of float stood at approximately 36% as of the end of June. This high level of short interest could contribute to further upward pressure on the stock price if short sellers are forced to cover their positions during the current rally. Investors will be closely watching Hims' earnings report, scheduled for August 4, for insights into the performance of its weight-loss business, which has been a focal point following recent controversies with

.

Comments



Add a public comment...
No comments

No comments yet